Therapy of type 2 diabetes, cardiovascular death, and the UGDP.
Feinglos
M N
MN
Division of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Bethel
M A
MA
D015906:Angioplasty, Balloon, Coronary; D001786:Blood Glucose / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality* / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000627:therapeutic use*; D011446:Prospective Studies; D012307:Risk Factors; D015996:Survival Rate; D014044:Tolbutamide / Q000627:therapeutic use*; D016896:Treatment Outcome; D014495:Universities
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D014044:Tolbutamide; D010629:Phenformin